Despite advances in pharmacological therapies, migraine patients are often drug resistant. Further therapeutic options in this field are, therefore, desirable. Recent studies have highlighted the efficacy of ketogenic diet (KD) on improving migraine, but data on their long-term efficacy and safety are lacking. In this study, we retrospectively evaluated the long-term effectiveness of the modified Atkins ketogenic diet (MAD) in episodic or chronic drug-resistant migraine patients. 52 patients diagnosed with episodic or chronic drug-resistant migraine under modified Atkins ketogenic diet (MAD) were evaluated. In total, 41 patients followed the diet for 6 months and 33 for 12 months. After both 6 and 12 months, frequency, length, and intensity of migraine episodes, as well as the number of medications significantly decreased with respect to the start of the diet. Body mass index, high sensitivity PCR, diastolic blood pressure, fasting plasma insulin and HOMA index were also significantly reduced both after 6 and 12 months. No major metabolic changes were observed during MAD treatment. In conclusion, KD has been shown to be effective and safe in the long-term treatment of drug-resistant migraine. A high dropout rate still remains an important factor, which often limits its use.
10 October 2026 in Applied Psychophysiology and Biofeedback
Background: Chronic pain patients often exhibit altered processing of internal bodily sensations, especially in the musculoskeletal domain, and impaired body awareness. This case-control study investigated the association between resting electromyographic (EMG) activity, musculoskeletal tension discrimination and body awareness in chronic headache (CH) patients compared to healthy controls (HC). Methods: Twenty-one patients diagnosed with chronic headache and 22 matched healthy controls performed a muscle tension discrimination task while EMG was recorded from the frontalis (pain-related) and biceps brachii (pain-unrelated) muscles. Questionnaires assessed body awareness and pain-related cognitive and affective factors. Results: Compared to HC, CH patients showed higher resting muscle activity (β = 1.32; p < 0.001) and lower discrimination (β = -0.12; p = 0.007) only in the pain site. CH patients exhibited reduced body awareness (η² p = 0.19; p = 0.003), higher anxiety (β = 3.10; p = 0.032), catastrophizing (η² p = 0.30; p < 0.001), and helplessness (η² p = 0.19; p = 0.004). Notably, lower muscle tension discrimination was associated with both higher resting frontalis EMG (ρs = -0.31; p = 0.043) and catastrophizing (ρs = -0.39; p = 0.009). Conclusions: Patients with CH exhibit a site-specific deficit in muscle tension discrimination, accompanied by elevated resting pericranial muscle tension, reduced body awareness, and maladaptive cognitive coping strategies. The association between catastrophizing and impaired discrimination highlights the interplay between cognitive-affective factors and psychophysiological dysregulation in CH. These findings underscore the importance of multidimensional assessment in patients with CH in order to identify targeted psychophysiological treatment.